ArticleClinical drug investigation2024

Neurological and Psychiatric Adverse Events Associated with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer Patients: Insights from a Pharmacovigilance Study via the FDA Adverse Event Reporting System.

Zicheng Yu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.